Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.1.52 (
PNGase F
)
1,527
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
CD94
NK cell receptor is assembled as a disulfide-linked dimer and appears to be encoded by a single-copy gene of the C-type lectin superfamily. In reverse Ab-dependent cellular cytotoxicity assays,
CD94
-specific mAbs may either trigger or inhibit cytotoxicity in distinct subsets of NK clones, termed groups A and B, respectively. The molecular basis for this functional ambivalence of
CD94
has been addressed.
CD94
molecules immunoprecipitated with the HP-3B1 mAb from the two different subsets of NK clones were comparatively analyzed by SDS-PAGE. Under reducing conditions, the stimulating form of
CD94
from group A clones displayed a significantly lower Mr (39 kDa) than the inhibitory form of group B clones (Mr = 43 kDa). Analyses of
N-glycanase
and V8 protease-digested samples indicated that the two
CD94
forms are homologous. A
CD94
-specific mAb (Z199) that did not recognize cells transfected with a
CD94
cDNA (LL288) was characterized. Z199 did not bind to group A clones, whereas its reactivity with group B NK cells was indistinguishable from that of other
CD94
-specific mAbs. Different from the HP-3B1 mAb, the Z199 mAb displayed only inhibitory effects in reverse Ab-dependent cellular cytotoxicity assays. Immunoprecipitation studies confirmed that Z199 selectively identified the 43-kDa
CD94
. Our study proves the existence of at least two biochemically and serologically distinct
CD94
molecules, whose selective/predominant expression at the clonal level correlates with the pattern of response (i.e., inhibition vs activation) of NK cells to ligation by
CD94
-specific mAbs.
...
PMID:Biochemical and serologic evidence for the existence of functionally distinct forms of the CD94 NK cell receptor. 895 84